IPO Week Preview — Story-Led Edition

Edition: November 8, 2026 · Research cutoff: November 8, 2026 · Coverage: November 9–15, 2026

With staff and AI research assistance

By Frank Whitaker and Stan Rosenberg

IPOs This Week at a Glance

| Company | Expected date | Price range | Status | Evidence |

|---|---|---|---|---|

| [Primagrove Ltd.](#primagrove) | Nov 9* | $4–$6 | Filed; pricing window tentative | [Purple · Mixed evidence found](#evidence-primagrove) |

| [Deep Sea Minerals](#deepsea) | Nov 10* | $4.25–$8 per ADS + warrant | Proposed U.S. ADS offer; tentative | [Blue · Strong evidence found](#evidence-deepsea) |

| [Rezera Inc.](#rezera) | Nov 12* | $11–$13 | S-1/A filed; expected week | [Blue · Strong evidence found](#evidence-rezera) |

| [vVARDIS Holding AG](#vvardis) | Nov 12 pricing; Nov 13 trade | $21–$24 | NYSE-approved; expected | [Purple · Mixed evidence found](#evidence-vvardis) |

| [Starton Holdings, Inc.](#starton) | Nov 13* | $5–$7 | S-1/A filed; expected week | [Purple · Mixed evidence found](#evidence-starton) |

Dates marked * are tentative tracker expectations. Primagrove trackers conflict: Webull lists a Nov. 9 listing, while IPOScoop and MarketBeat show Nov. 16. We show Nov. 9 as a tentative pricing window; no first-trade date in this seven-day period was independently verified. vVARDIS pricing and trading are separate calendar events. DDC’s SVOR issue is a proposed preferred-share offering by an already-listed company, not an IPO, and is not counted.

IPOs in the News at a Glance

| Company | Expected date | Price range | Status | Evidence |

|---|---|---|---|---|

| [Anthropic PBC](#anthropic) | Not set | Not set | Public S-1/A filed; terms not set | [Blue · Strong evidence found](#evidence-anthropic) |

| [Crescent Royalties](#crescent) | Not set | Not set | Confidential draft; no terms | [Pink · Limited evidence found](#evidence-crescent) |

| [Harvey](#harvey) | Not set | Not set | Early adviser talks reported; no filing | [Pink · Limited evidence found](#evidence-harvey) |

Publicity is not proof of an imminent IPO or investment quality. The three were selected for substantial, verifiable coverage in November; no public date or range was set where shown Not set.

Key Takeaways

• Five calendar-tracked events fall inside the seven-day window, but two are not conventional first-time listings: Deep Sea Minerals is a U.S. ADS offer by an already-public issuer, and vVARDIS has distinct pricing and first-trading dates.

• Rezera’s proposed $200 million midpoint IPO funds a clinical-stage biotech whose lead drug remains unapproved; the conditional GSK participation is not a guaranteed investment.

• vVARDIS combines fast-growing dental-product sales with substantial losses, founder voting control and disclosed founder share pledges tied to personal debt.

• Starton’s prospectus describes a 2017-founded cancer-drug developer with no approved products, ongoing losses and a stated going-concern warning.

• IPO publicity is not evidence of readiness or quality: the news list includes one public registration filing, one confidential draft, and one reported preliminary discussion.

The week’s story

This week mixes first-time IPOs with a U.S. offer from an issuer already public elsewhere. Dates are estimates; filings show what the money funds and which milestones remain.

This Week’s Offerings

<a id="primagrove"></a>

Primagrove Ltd. | YHTE

Primagrove is a Cayman holding company formed in February 2026; Hong Kong subsidiary Oceanic Bounty dates to 2023. Oceanic sells software-enabled workspace solutions and provides systems and website development. The $4–$6 offer is for 6.25 million parent shares; Nasdaq approval remains a condition. CEO-chair Lixia He controls the company. Oceanic reported $1.83 million revenue and $1.07 million net income in 2025. Calendars disagree on Nov. 9 versus Nov. 16, so pricing remains tentative.

Evidence: [Purple · Mixed evidence found](#evidence-primagrove)

<a id="deepsea"></a>

Deep Sea Minerals | SEAM

Deep Sea Minerals already trades publicly outside the United States, so this proposed U.S. ADS offer is not a first listing. The October filing proposes 833,334 units, each an ADS representing 12 ordinary shares plus a warrant, at $4.25–$8. Proceeds would fund applications and preparation, not offshore mining. The company reports no acquired subsea rights; its NOAA application is not an approved license. Nov. 10 remains tentative.

Evidence: [Blue · Strong evidence found](#evidence-deepsea)

<a id="rezera"></a>

Rezera Inc. | RZRA

Founded in 2016 as NodThera, Rezera changed its name in September. It is developing oral inflammatory-disease drugs; lead candidate ruvonoflast is still clinical-stage. CEO Geoff McDonough previously led Generation Bio through an IPO and held senior roles at Sobi and Genzyme. The S-1/A proposes 16.67 million shares at $11–$13, about $200 million gross at midpoint. June cash was $3.9 million against a $210.7 million accumulated deficit. A possible $25 million GSK order is conditional, not assured. Clinical results, dilution and financing needs remain key unknowns.

Evidence: [Blue · Strong evidence found](#evidence-rezera)

<a id="vvardis"></a>

vVARDIS Holding AG | VVVV

Swiss dental-products company vVARDIS is led by dentist co-founders and co-CEOs Haley and Goly Abivardi, who previously built Swiss Smile and an oral-care brand. Its amended filing offers 9.52 million new shares at $21–$24; calendars expect pricing Nov. 12 and trading Nov. 13. Revenue was $49.7 million and net loss $52.2 million in the 12 months through June 2026. It also discloses dual-class founder control and founder shares pledged for personal loans. These terms deserve attention alongside growth.

Evidence: [Purple · Mixed evidence found](#evidence-vvardis)

<a id="starton"></a>

Starton Holdings, Inc. | STA

Starton develops continuous-delivery cancer-drug candidates; none is FDA-approved. Its business began in 2017 and reorganized under a Delaware parent in 2025. CEO Pedro Lichtinger previously led Asterias and Optimer and held senior Pfizer roles. The S-1/A proposes five million shares at $5–$7. It reports a $15.4 million FY2026 loss, $89.2 million accumulated deficit and substantial doubt about continuing as a going concern. Proceeds would support operations and development, but clinical, regulatory and financing milestones remain ahead.

Evidence: [Purple · Mixed evidence found](#evidence-starton)

In the News

<a id="anthropic"></a>

Anthropic PBC

Filed Oct. 26; amended Nov. 2; its very large reported revenue and losses have drawn coverage.

<a id="crescent"></a>

Crescent Royalties

Crescent Energy disclosed a confidential draft filing for a royalty subsidiary; asset and deal details remain limited.

<a id="harvey"></a>

Harvey

Recent reporting describes early IPO-adviser conversations; no public timetable or terms are available.

Evidence We Found

Legend: Blue — Strong evidence found · Purple — Mixed evidence found · Pink — Limited evidence found · Beach sand — Not enough evidence located. These colors describe the amount and consistency of relevant evidence located, not a recommendation, company-quality rating or performance signal. “Not enough evidence located” means this search found insufficient reliable material; it does not mean the information does not exist.

<a id="evidence-primagrove"></a>

Primagrove · Purple · Mixed evidence found

SEC F-1 provides corporate structure, offering terms, audited results and management. Oceanic reported 2025 revenue of $1.83M and net income of $1.07M (2024: $98K revenue, $21K net income); project revenue may fluctuate. He is CEO/chair; director nominees: Kevin Kwok, Henry Cheng and Qian He. Gap: trackers conflict; Nasdaq approval was not yet granted. No separate pre-IPO fundraise is identified beyond internal share reorganization/allocation.

<a id="evidence-deepsea"></a>

Deep Sea Minerals · Blue · Strong evidence found

SEC prospectus details ADS/warrant terms, intended proceeds and no acquired subsea rights; its NOAA application is not a license. The company closed a $4.22M non-brokered private placement in February 2026. CEO James Deckelman; directors listed in filings include Steven Nguyen, Geoff Balderson, Anthony Zelen and Jeremy Perez. Gap: final U.S. price, proceeds and regulatory outcome.

<a id="evidence-rezera"></a>

Rezera · Blue · Strong evidence found

Reuters reports about $200M raised in equity financing since 2016; July 2026 Series D4 delivered about $15M net and a $15M term loan was borrowed. CEO Geoff McDonough; directors after the planned transitions: Donald Nicholson, Elisabeth Björk, Henrijette Richter, Scott Rocklage and McDonough. Gap: actual GSK order and trial outcomes.

<a id="evidence-vvardis"></a>

vVARDIS · Purple · Mixed evidence found

SEC F-1/A, Nov. 6, identifies co-CEOs/co-founders Haley and Goly Abivardi, CFO/CPO Thomas Rondot, and directors Juergen Stark and Clifford zur Nieden; it details financials, dual-class control and founder share pledges. Apollo-managed funds made a strategic minority investment in April 2026; amount undisclosed. Gap: final price and whether estimated growth materializes.

<a id="evidence-starton"></a>

Starton · Purple · Mixed evidence found

SEC S-1/A documents 2017 operating history and 2025 reorganization. CEO Pedro Lichtinger; directors Eric Baum, Moses Dodo, Nitin Kaushal and Roy F. Waldron. The filing lists related-party/management loans, including $660K in May 2026. Losses, cash needs and going-concern warning are disclosed. Gap: no product approval or commercial revenue.

<a id="evidence-anthropic"></a>

Anthropic · Blue · Strong evidence found

Public S-1/A and independent AP/Reuters reporting available. Public date and price remain unset. Reported scale should be read alongside reported losses and filing assumptions.

<a id="evidence-crescent"></a>

Crescent Royalties · Pink · Limited evidence found

Parent’s SEC report, company announcement and Reuters confirm confidential draft submission. Confidential draft means detailed proposed assets and terms are not public in the materials reviewed.

<a id="evidence-harvey"></a>

Harvey · Pink · Limited evidence found

Independent reports describe preliminary adviser discussions. No public registration filing, offering range or schedule was located by the cutoff; absence of a filing in this search is not proof no private preparation exists.

Offer size context

[View the proceeds-range chart](ipo-offer-size-ranges-2026-11-08.png). Gross proceeds use indicative shares/units × price range; before fees; excludes valuation comparison. Deep Sea unit includes ADS and warrant.

Sources and research notes

SEC filings and public records

• Primagrove F-1, Sept. 30

• Primagrove filing index

• Rezera S-1/A, Nov. 5

• vVARDIS F-1/A, Nov. 6

• Starton S-1/A, Oct. 28

• Deep Sea Minerals prospectus supplement

• Deep Sea Minerals Form 6-K CFO update

• DDC preferred share prospectus supplement

• Anthropic S-1/A, Nov. 2

• Crescent Energy parent 10-Q

Company materials

• Rezera leadership biographies

• Starton leadership biographies

• Deep Sea Minerals offering announcement

• Crescent Energy announcement via Nasdaq

Independent reporting

• Reuters: Rezera IPO and conditional GSK order

• Reuters: vVARDIS offering and valuation

• AP: Anthropic IPO filing coverage

• Reuters: Anthropic timing discussion

• Reuters: Crescent Royalties filing

• Business Insider: Harvey preliminary talks

• Legal Business: Harvey adviser discussions

Calendar cross-checks

• IPOScoop current IPO calendar

• Webull current IPO offering calendar

• vVARDIS pricing/trading date tracker

Sources were checked through November 8, 2026. Primary filings and company materials were prioritized; dates remain tentative until final pricing/exchange notices.

AI research note: AI tools can misread filings, confuse planned events with completed events, or repeat unsupported claims. Verify important findings against linked originals.

This report is editorial information, not investment advice.